GENELUX CORPORATION Increase (Decrease) in Interest Payable, Net
GENELUX CORPORATION (GNLX) reported Increase (Decrease) in Interest Payable, Net of $22.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2025-03-28
- GENELUX CORPORATION increase (decrease) in interest payable, net for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in interest payable, net for the quarter ending 2023-09-30 was -$22.00K, a 108.94% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in interest payable, net for the quarter ending 2023-06-30 was -$48.00K, a 119.51% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in interest payable, net for the quarter ending 2023-03-31 was $92.00K, a 35.21% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in interest payable, net for fiscal 2023 was $22.00K, a 97.52% decline from fiscal 2022.
- GENELUX CORPORATION increase (decrease) in interest payable, net for fiscal 2022 was $886.00K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$22.00K derived: sum of 2 quarters · filed 2025-03-28 | -$70.00K derived: sum of 3 quarters · filed 2025-03-28 | $22.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$70.00K derived: sum of 2 quarters · filed 2024-11-14 | $22.00K 10-Q · filed 2024-11-14 | $274.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $44.00K 10-Q · filed 2024-08-14 | $296.00K derived: sum of 3 quarters · filed 2024-08-14 | $542.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $92.00K 10-Q · filed 2024-05-09 | $344.00K derived: sum of 2 quarters · filed 2024-05-09 | $590.00K derived: sum of 3 quarters · filed 2024-05-09 | $836.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $498.00K derived: sum of 2 quarters · filed 2024-03-29 | $744.00K derived: sum of 3 quarters · filed 2024-03-29 | $886.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $492.00K derived: sum of 2 quarters · filed 2023-11-14 | $634.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $388.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $142.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |